Bristol Myers Excedrin
Check against the official notice below — it lists the full affected range.
Bristol Myers Products and the Consumer Product Safety Commission announced on June 7, 1977, that certain packages of Excedrin analgesic tablets failed to meet federal child-resistant packaging requirements. The affected products were 225-tablet and 375-tablet package sizes distributed nationwide prior to April 1977. CPSC testing identified the packaging compliance failure, which posed a poisoning hazard.
The company initiated a product substitution program covering approximately 150,000 packages representing about 81% of major wholesale and retail inventory. Bristol Myers retrieved the non-compliant packages and replaced them with upgraded, tested versions by mid-June 1977. The company also improved packaging for these sizes and expanded its quality control program. The record does not specify what actions an affected consumer should take.
Written by software from the official notice below. Not reviewed by a lawyer.
Poisoning
Product Substitution For Excedrin Announced NEWS from CPSC U.S. Consumer Product Safety Commission Office of Information and Public Affairs Washington, DC 20207 FOR IMMEDIATE RELEASE June 7, 1977 Release # 77-059 Product Substitution For Excedrin Announced WASHINGTON, D.C. (June 7) -- Bristol Myers Products, a division of Bristol Myers Company, and the Consumer Product Safety Commission (CPSC) announced today a product substitution of the company's 225 tablet package size and 375 tablet size of Excedrin analgesic tablets which were distributed nationwide prior to April 1977. CPSC testing found same packages for this product failed to comply with Federal regulations requiring that the packages be child-resistant. The product substitution covers warehouse inventories of those major wholesale and retail customers handling approximately 81% of the merchandise. Existing inventories of these packages are being retrieved and replaced by upgraded packages which were tested by Bristol Myers to assure CPSC compliance. The product substitution will involve approximately 150,000 packages and will be completed by the middle of June. These two sizes represent less than 3% of Excedrin analgesic annual unit sales volume. Bristol Myers Products, in addition, has improved its packages for these sizes of Excedrin analgesic products and has expanded its quality control program to reduce the likelihood of similar situations arising in the future. This program is not a substitute for any legal action which may be deemed necessary by CPSC.
Official record: U.S. Consumer Product Safety Commission ↗
Republished from the official source above; details can change — the source record controls.